AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30626191 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based medication adherence support intervention (real-time adherence monitors linked to SMS text messages)
Number of subjects: 28
Study 30626202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in BAV patients
Number of subjects: 101
Study 30626202 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation in TAV patients
Number of subjects: 101
Study 30626202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in both BAV and TAV patients
Number of subjects: 101
Study 30626203 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-Tei (≥0.45)
Number of subjects: 824
Study 30626203 — intervention group
Group type: COMPARATOR
Intervention: Normal pre-Tei (<0.45)
Number of subjects: 824
Study 30626203 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Tei normal
Number of subjects: 824
Study 30626203 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Tei high
Number of subjects: 824
Study 30626238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly
Number of subjects: 50
Study 30626327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden Markov Models (HMMs) applied to reassurance types from audio files of consultations.
Number of subjects: 0
Study 30626372 — intervention group
Group type: EXPERIMENTAL
Intervention: Past 12-month discrimination, unemployment, lifetime intimate partner violence (IPV)
Number of subjects: 150
Study 30626372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment, past 12-month discrimination
Number of subjects: 150
Study 30626372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low annual household income, past 12-month discrimination
Number of subjects: 150
Study 30626372 — intervention group
Group type: EXPERIMENTAL
Intervention: Past 12-month discrimination
Number of subjects: 150
Study 30626372 — intervention group
Group type: COMPARATOR
Intervention: Having a partner
Number of subjects: 150
Study 30626372 — intervention group
Group type: COMPARATOR
Intervention: Greater resilience
Number of subjects: 150
Study 30626372 — intervention group
Group type: COMPARATOR
Intervention: Resilience
Number of subjects: 150
Study 30626372 — intervention group
Group type: COMPARATOR
Intervention: Higher age, greater resilience
Number of subjects: 150
Study 30626404 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital ECG recording
Number of subjects: 520
Study 30626404 — intervention group
Group type: EXPERIMENTAL
Intervention: IV access established during transportation
Number of subjects: 520
Study 30626404 — intervention group
Group type: EXPERIMENTAL
Intervention: Good communication with stroke centres
Number of subjects: 520
Study 30626544 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C sub-particles
Number of subjects: 304
Study 30626544 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 304
Study 30626567 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction during IV procedures
Number of subjects: 25
Study 30626567 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) distraction during IV procedures
Number of subjects: 25
Study 30626567 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 25
Study 30626633 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT at presentation >14 ng/L
Number of subjects: 3828
Study 30626633 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT at presentation >52 ng/L
Number of subjects: 3828
Study 30626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cTn concentrations alone and in combination with early changes
Number of subjects: 3828
Study 30626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sampling
Number of subjects: 3828
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional measures (a-NSAA, MFM-20, timed function tests, 6MWT, Brooke scale, Jebsen test, manual muscle testing, hand-held dynamometry, ACTIVLIM questionnaire)
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: a-NSAA score
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-meter walk test
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: MFM domain 3, wrist flexion strength, pinch grip
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression rates
Number of subjects: 193
Study 30626655 — intervention group
Group type: EXPERIMENTAL
Intervention: Power calculations
Number of subjects: 193
Study 30626746 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine daily for 7 days
Number of subjects: 10
Study 30628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria prevention strategies in pregnancy
Number of subjects: 1
Study 30629045 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (PA) tertile
Number of subjects: 4034
Study 30629045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity (PA) tertile
Number of subjects: 4034
Study 30629045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical modeling
Number of subjects: 4034
Study 30629195 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) for 2 weeks
Number of subjects: 124
Study 30629202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (sTfR >6.0 mg/L) in early pregnancy
Number of subjects: 2379
Study 30629202 — intervention group
Group type: EXPERIMENTAL
Intervention: Replete iron status (sTfR <10th percentile) in early pregnancy
Number of subjects: 2379
Study 30629202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency in late pregnancy
Number of subjects: 2379
Study 30629202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-replete status in late pregnancy
Number of subjects: 2379
Study 30630356 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in low-surgical risk patients (logES <10%)
Number of subjects: 1785
Study 30630356 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in intermediate-surgical risk patients (logES 10%-20%)
Number of subjects: 1785
Study 30630356 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in high-surgical risk patients (logES ≥20%)
Number of subjects: 1785
Study 30630356 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) across all risk categories
Number of subjects: 1785
Study 30630355 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon Treatment
Number of subjects: 0
Study 30630355 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30630358 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30630419 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Lip Bite Test (ULBT)
Number of subjects: 344
Study 30630419 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati (MMT) classification
Number of subjects: 344
Study 30630452 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (IIM) 5% (Diafer®)
Number of subjects: 198
Study 30630452 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 198
Study 30630502 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 5 Gy of high-precision radiotherapy to the dominant symptomatic lesion and 4 × 7 Gy to the most aggressive part of the lesion using a simultaneous integrated boost technique.
Number of subjects: 34
Study 30630632 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher zBMI
Number of subjects: 1607
Study 30630632 — intervention group
Group type: COMPARATOR
Intervention: Low-grade inflammation (CRP >1.0 mg/L to <10.0 mg/L)
Number of subjects: 1607
Study 30630885 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab
Number of subjects: 1300
Study 30630885 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with paclitaxel, carboplatin, and bevacizumab
Number of subjects: 1300
Study 30630956 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U
Number of subjects: 715
Study 30630975 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-1 (300 cGy)
Number of subjects: 77
Study 30630975 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-2 (400 cGy)
Number of subjects: 77
Study 30630975 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-3 (450 cGy)
Number of subjects: 77
Study 30631299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Modality Brain Injury Assessments
Number of subjects: 0
Study 30631878 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood lead (BL) levels
Number of subjects: 339
Study 30631878 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop test (ST)
Number of subjects: 339
Study 30631878 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit-symbol test (DST)
Number of subjects: 339
Study 30632302 — intervention group
Group type: COMPARATOR
Intervention: Control (1-min control)
Number of subjects: 40
Study 30632302 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructed breathing (1 min)
Number of subjects: 40
Study 30632847 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase treatment
Number of subjects: 0
Study 30633128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with paclitaxel and a platinum compound
Number of subjects: 4739
Study 30633128 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to recurrence after initial chemotherapy
Number of subjects: 4739
Study 30633128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival after recurrence
Number of subjects: 4739
Study 30633128 — intervention group
Group type: EXPERIMENTAL
Intervention: Second look laparotomy with complete pathologic response or intraperitoneal chemotherapy
Number of subjects: 4739
Study 30633573 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib 400 mg BID
Number of subjects: 49
Study 30634942 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (30 mg) as add-on to gemcitabine/cisplatin (80% standard dose)
Number of subjects: 9
Study 30634955 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) intervention
Number of subjects: 0
Study 30634955 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation process
Number of subjects: 0
Study 30634988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory group of DS patients (37 patients)
Number of subjects: 101
Study 30634988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized group of DS patients (64 patients)
Number of subjects: 101
Study 30635024 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED) at 640 kcal/day for 12-16 weeks, followed by a gradual reintroduction of an energy-restricted diet.
Number of subjects: 41
Study 30635024 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED) at 640 kcal/day for 12-16 weeks.
Number of subjects: 41
Study 30635165 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 40 mg BID with gemcitabine 400 mg/m² and daily IMRT
Number of subjects: 30
Study 30635261 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Circles
Number of subjects: 250
Study 30635261 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 250
Study 30635336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of palbociclib (75 mg) and paclitaxel (80 mg/m2)
Number of subjects: 27
Study 30635336 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib alone
Number of subjects: 27
Study 30635409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition white light (WL)
Number of subjects: 230
Study 30635409 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 230
Study 30635409 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging with near focus (NBI-NF)
Number of subjects: 230
Study 30635409 — intervention group
Group type: EXPERIMENTAL
Intervention: WL with near focus (WL-NF)
Number of subjects: 230
Study 30635409 — intervention group
Group type: COMPARATOR
Intervention: Offline assessment by experienced endoscopists
Number of subjects: 230
Study 30635495 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care strategies provided by hospitals
Number of subjects: 41
Study 30635495 — intervention group
Group type: COMPARATOR
Intervention: Hospitals that met the TCM definition
Number of subjects: 41
Study 30635495 — intervention group
Group type: COMPARATOR
Intervention: Stroke center certification, Magnet designation, and use of TCM billing codes
Number of subjects: 41
Study 30636101 — intervention group
Group type: EXPERIMENTAL
Intervention: hfTENS device (Quell, NeuroMetrix, Inc.) used daily for 3 months
Number of subjects: 68
Study 30636101 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 68
Study 30636249 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST) with a single dose of intravenous furosemide, 1.5 mg/kg at 3 h after allograft reperfusion
Number of subjects: 59
Study 30636249 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST)
Number of subjects: 59
Study 30636249 — intervention group
Group type: COMPARATOR
Intervention: Urine neutrophil gelatinase-associated lipocalin (NGAL), resistive index (RI) of renal arteries, effective renal plasma flow (ERPF)
Number of subjects: 59
Study 30636515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score quartiles
Number of subjects: 168
Study 30636515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score as a continuous variable
Number of subjects: 168
Study 30636515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score quartile cutoffs
Number of subjects: 168
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-fatty acids
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal MUFAs
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant MUFAs
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 PUFAs
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of 5% of energy from SFAs with plant MUFAs
Number of subjects: 521120
Study 30636521 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of 2% of energy from SFAs with linoleic acid
Number of subjects: 521120
Study 30637118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement with milk
Number of subjects: 60
Study 30637118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement with food
Number of subjects: 60
Study 30637118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement on an empty stomach
Number of subjects: 60
Study 30637118 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen fish oil capsules prior to ingestion
Number of subjects: 60
Study 30637134 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin therapy
Number of subjects: 2700
Study 30637134 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 2700
Study 30637483 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of obesity
Number of subjects: 671
Study 30637483 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IL-6
Number of subjects: 671
Study 30637570 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSAS
Number of subjects: 104
Study 30637570 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSAS
Number of subjects: 104
Study 30637570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSAS
Number of subjects: 104
Study 30637784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) with reduced toxicity preparative regimen of busulfan (13.2 mg/kg) and fludarabine (175 mg/m2)
Number of subjects: 0
Study 30638399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily
Number of subjects: 51
Study 30638769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 27
Study 30638769 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 27
Study 30638822 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC-eligible foods
Number of subjects: 2777
Study 30638822 — intervention group
Group type: COMPARATOR
Intervention: WIC participation
Number of subjects: 2777
Study 30638821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) intake adjusted for energy intake, MAR, and baseline socioeconomic status
Number of subjects: 720
Study 30638821 — intervention group
Group type: EXPERIMENTAL
Intervention: Water/sugar-free beverage intake adjusted for energy intake, MAR, and baseline socioeconomic status
Number of subjects: 720
Study 30638821 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% juice intake
Number of subjects: 720
Study 30638821 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 720
Study 30638856 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg) via subcutaneous injection every 2 weeks for 64 weeks, with possible increase to 1.2 mg/kg based on serum phosphorus levels.
Number of subjects: 13
Study 30638856 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 13
Study 30639779 — intervention group
Group type: EXPERIMENTAL
Intervention: CLDQ-NASH
Number of subjects: 1667
Study 30640246 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT surgical procedures
Number of subjects: 5572
Study 30640246 — intervention group
Group type: COMPARATOR
Intervention: Non-ENT surgical procedures
Number of subjects: 5572
Study 30640246 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 5572
Study 30640246 — intervention group
Group type: EXPERIMENTAL
Intervention: History of snoring, recent upper respiratory tract infection, recent wheezing
Number of subjects: 5572
Study 30640246 — intervention group
Group type: EXPERIMENTAL
Intervention: Age below 4.6 years and lower surgical volume thresholds (<20 cases/2 weeks)
Number of subjects: 5572
Study 30640659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (four incremental doses)
Number of subjects: 49
Study 30640659 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 49
Study 30640706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 300
Study 30640706 — intervention group
Group type: COMPARATOR
Intervention: Systematic pelvic lymphadenectomy
Number of subjects: 300
Study 30641227 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive molecular testing of nasopharyngeal and oropharyngeal swabs (NPS)
Number of subjects: 199
Study 30641227 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic tests (blood and sputum culture, urine antigen detection)
Number of subjects: 199
Study 30641478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 104
Study 30641478 — intervention group
Group type: COMPARATOR
Intervention: Emergency cesarean section
Number of subjects: 104
Study 30641478 — intervention group
Group type: COMPARATOR
Intervention: Planned cesarean section
Number of subjects: 104
Study 30641478 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 104
Study 30641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) optimization using singular value decomposition and minimization of field anisotropy (FA).
Number of subjects: 0
Study 30641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) optimization.
Number of subjects: 0
Study 30641533 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking capacity measured by Six Minutes Walking Test (6MWT)
Number of subjects: 48
Study 30641533 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain severity
Number of subjects: 48
Study 30641533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb strength
Number of subjects: 48
Study 30642285 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 3 cycles of cisplatin and pemetrexed
Number of subjects: 25
Study 30642285 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic responders on FDG-PET scan after chemotherapy
Number of subjects: 25
Study 30642285 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders on FDG-PET scan after chemotherapy
Number of subjects: 25
Study 30642290 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg IV every 4 weeks) and Tremelimumab (75 mg IV every 4 weeks for a total of 4 doses) with SBRT to 2-5 metastases
Number of subjects: 35
Study 30642290 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression Free Survival (PFS)
Number of subjects: 35
Study 30642302 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain abdominal radiography (PAR)
Number of subjects: 1997
Study 30642302 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to the private hospital ED
Number of subjects: 1997
Study 30642302 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1997
Study 30642302 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 1997